What's Going On With Neurological Disease Focused Trevena On Thursday?
What's Going On With Neurological Disease Focused Trevena On Thursday?
Shares of Trevena Inc (NASDAQ:TRVN) are trading lower on Thursday, with a session volume of 23.65 million, as per data from Benzinga Pro.
据Benzinga Pro的数据，Trevena Inc.（纳斯达克：TRVN）的股票在周四交易时出现下跌，成交量为2365万股。
The company released preclinical data from two separate research collaborations.
该公司发布了两个不同研究合作的临床前数据。
The first studies examined the cellular mechanism of analgesic effects of TRV045, a novel S1P1 receptor modulator, in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN).
第一项研究检查了TRV045的镇痛作用机制，TRV045是一种新型S1P1受体调节剂，检测采用化疗引起的外周神经病变（CIPN）小鼠模型。
The second set of studies was from a separate, ongoing collaboration with the NIH-supported Epilepsy Therapy Screening Program (ETSP), which studied the use of TRV045 in three different preclinical models, examining its potential effects on acute seizure protection and its potential ability to modify seizure development, or epileptogenesis.
第二组研究来自与美国国立卫生研究院支持的癫痫疗法筛选计划（ETSP）的另一个正在进行的合作项目，研究了TRV045在三种不同的临床前模型中的应用，研究其可能对急性癫痫发作的保护效应，并研究其可能修改发作和癫痫发展。
In this study, TRV045 did not cause S1P1R functional desensitization or S1PR1 protein reduction despite repeated dosing over 14 days.
在这项研究中，在14天的重复给药过程中，TRV045并没有引起S1P1R功能性失效或S1PR1蛋白降低。
In contrast, Novartis AG's (NYSE:NVS) Gilenya (fingolimod), an approved S1PR modulator, demonstrated significant S1P1R functional desensitization and protein reduction in this model.
相反，诺华制药（纽交所：NVS）的Gilenya（指甲酸酯），一种S1PR调节剂，证实该模型中的S1P1R功能性失效和蛋白降低显著。
Repeated fingolimod (1 mg/kg, once a day for 14 days) dosing decreased such 35SGTPgS binding by approximately 70% compared with vehicle, while repeated TRV045 oral dosing (10 mg/kg, once a day for 14 days) had no effect.
在这种模型中，重复的Gilenya（1mg/kg，每天一次，持续14天）给药导致约70%的35SGTPgS结合相比于用车剂时下降。而重复的TRV045口服给药（每天10mg/kg，持续14天）没有任何影响。
S1PR1 protein expression indicated that repeated fingolimod treatment caused an approximately 30% reduction in S1P1R protein in the spinal cord, while repeated TRV045 treatment had no effect.
S1PR1蛋白表达表明，重复的Gilenya治疗导致脊髓S1P1R蛋白降低约30%，而重复的TRV045治疗没有任何影响。
Similar effects were seen in the region of the periaqueductal gray; both regions play important roles in pain transmission.
类似的效果也在中脑导水管周围灰质区域中看到；这两个区域在疼痛传导中起着重要作用。
A validated model of seizure induction in mice was used in a preclinical study.
小鼠诱发癫痫研究采用了一个经过验证的模型。
At the 30mg/kg dose, TRV045 demonstrated a statistically significant increase in time to the first myoclonic (whole-body) twitch (31.6 seconds TRV045 vs 26.0 seconds vehicle, p=0.02).
在30mg/kg的剂量下，TRV045表现出统计学显著延迟首个肌阵挛（全身）抽搐的时间（31.6秒TRV045对比26.0秒车剂，P=0.02）。
This dose of TRV045 also demonstrated an increase in the time to generalized clonus (33.9 seconds TRV045 vs. 28.7 seconds vehicle, p=0.056).
这个剂量的TRV045也展现出了延迟全身阵挛发生的时间（33.9秒TRV045对比28.7秒车剂，P=0.056）。
A separate study used a validated model of acute anti-seizure effect in rats. A dose-dependent protection was observed across the dose range, reaching 7 of 8 rats protected at the 30 mg/kg dose level and an estimated effective dose for 50% of the population (ED50) of 18 mg/kg.
另一项研究采用了大鼠急性抗癫痫效应的经过验证的模型。在剂量范围内观察到了剂量依赖性的保护效果，在30mg/kg剂量中可保护8只大鼠中的7只，50%人群的有效剂量估计值（ED50）为18mg/kg。
The NIH-supported Epilepsy Therapy Screening Program plans to initiate additional studies of the anti-seizure potential of TRV045.
美国国立卫生研究院支持的癫痫疗法筛选计划计划启动TRV045的抗癫痫潜力的其他研究。
Although the initial assessment of the potential anti-epileptogenic effect of TRV045 did not demonstrate a statistically significant difference on the outcomes studied here, these results will assist in subsequent considerations of other dose and treatment duration in future seizure prevention studies.
尽管TRV045的潜在抗癫痫效应的最初评估在此处研究的结果上没有表现出显著差异，但这些结果将有助于今后考虑其他剂量和治疗持续时间以进行癫痫预防研究。
Price Action: TRVN shares are down 33.7% at $0.2349 at last check Thursday.
截至周四最新数据，TRVN股票下跌33.7%，为0.2349美元。
Photo via Shutterstock
图片来自shutterstock。